New Hope for Prostate Cancer Patients5 April 2012
Prostate Cancer Foundation (PCF) has funded a study to carry out the use of nanotechnology for drug delivery and researchers at David H. Koch Institute for Integrative Cancer Research, MIT in Phase 1 clinical trial of has used the first nanomedicine BIND 014 successfully for directly delivering the drug to the cancer cells. The research results have recently been published in Science Translational Medicine.
BIND Biosciences developed BIND 014, which is a nanomedicine that combines a ligands and nanoparticle Â and this nanomedicine contains the proven cancer medicine docetaxel encapsulated by FDA approved and biodegradable polymers. Ocetaxel has successfully been used in treating a large numbers of cancer cells including breast cancer cells, lung cancer cells and prostate cancer cells.
The nanomedicine BIND 014 is designed to target prostate specific membrane antigen (PSMA). The nanomedcine was designed to over-deliver the medicine at the tumor cell and the increased availability of the drug at the cancer cell translates significant improvement in anti-tumor activity. Although BIND 014 are being used for over a decade now for targeting PSMA but the current study also established that PSMA is also found on the surfaces of new blood vessels of other cancers.
It will look like this: New Hope for Prostate Cancer Patients